Advances in the management of systemic lupus erythematosus
- PMID: 37884289
- DOI: 10.1136/bmj-2022-073980
Advances in the management of systemic lupus erythematosus
Abstract
Systemic lupus erythematosus (SLE) is a severe multisystem autoimmune disease that can cause injury in almost every body system. While considered a classic example of autoimmunity, it is still relatively poorly understood. Treatment with immunosuppressive agents is challenging, as many agents are relatively non-specific, and the underlying disease is characterized by unpredictable flares and remissions. This State of The Art Review provides a comprehensive current summary of systemic lupus erythematosus based on recent literature. In basic and translational science, this summary includes the current state of genetics, epigenetics, differences by ancestry, and updates about the molecular and immunological pathogenesis of systemic lupus erythematosus. In clinical science, the summary includes updates in diagnosis and classification, clinical features and subphenotypes, and current guidelines and strategies for treatment. The paper also provides a comprehensive review of the large number of recent clinical trials in systemic lupus erythematosus. Current knowns and unknowns are presented, and potential directions for the future are suggested. Improved knowledge of immunological pathogenesis and the molecular differences that exist between patients should help to personalize treatment, minimize side effects, and achieve better outcomes in this difficult disease.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Conflict of interest statement
Competing interests: We have read and understood the BMJ policy on declaration of interests and declare the following interests: EFM receives research funding from the National Health and Medical Research Council of Australia, Lupus Research Alliance, AbbVie, Amgen, AstraZeneca, Biogen, BristolMyersSquibb, Eli Lilly, EMD Serono, Genentech, GSK, Janssen, and UCB; and consulting fees from AbbVie, AstraZeneca, Biogen, BristolMyersSquibb, Capella, Eli Lilly, EMD Serono, Genentech, Gilead, Novartis, and Zenas. RFR receives research funding from the Lupus Research Alliance Diversity in Lupus Research Career Development Award. AB receives research funding from the Lupus Research Alliance Diversity in Lupus Research Career Development Award and the National Institutes of Health K23AI163359; and consulting fees from GSK, Novartis, and UCB. TBN receives research funding from EMD Serono, Zenas Biopharma, NIH (AI164968, DK107984, AI167271, AR078416, AR065964), and the Lupus Research Foundation; and consulting fees from AstraZeneca, Progentec, S3 Connected Health, GSK, Thermo Fisher, Roivant Sciences, Ventus, Toran, and Inova.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical